RxDoctor Payments Data

James Joye, DO

Interventional Cardiology · Mountain View, CANPI 1396751889

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (35.5%), other and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Angiodynamics, Inc. at 51.6% of the total. 2025 is the largest year on record at $34,475, more than ten times the $489 reported in 2019.

$95,545in general payments, 2019–2025

Across 103 payments — averaging $927.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$49K
  • Endologix LLC$45K
  • Smith+Nephew$226
  • Organogenesis Inc.$182
  • Bard Peripheral Vascular, Inc.$173
  • Abbott$150
  • plus $561 from 9 others
$43,798in research payments, 2019–2025

Across 29 payments — averaging $1510.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$36K
  • Cordis Corporation$8K

What the payments were for

  • Consulting fees$33,90035%
  • Travel & lodging$6,0596%
  • Food & beverage$6,3367%
  • Education$19,25020%
  • Other$30,00031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Angiodynamics, Inc.5$49,276
Endologix LLC60$44,977
Smith+Nephew2$226
Organogenesis Inc.7$182
Bard Peripheral Vascular, Inc.1$173
Abbott4$150
Medtronic(2 entities)5$133
Bardy Diagnostics, Inc.5$123
Boston Scientific6$111
Baxter Healthcare3$82
Amgen1$29
Venclose Inc.1$24
Cordis US CORP.1$23
W. L. Gore & Associates, Inc.1$21
E.r. Squibb & Sons, L.L.C.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,545 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024
$5,148,333
Medicare patients
2,721
Services billed
12,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$112,256
Repatha SureclickEvolocumab40$34,974
XareltoRivaroxaban35$33,030
EntrestoSacubitril/Valsartan30$25,628
Praluent PenAlirocumab11$5,308
ClopidogrelClopidogrel Bisulfate346$4,846
Metoprolol Succinate150$2,753
Atorvastatin Calcium201$2,526
Rosuvastatin Calcium118$1,782
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$1,470
Potassium Chloride58$1,251
Ezetimibe55$1,044
Pantoprazole Sodium67$700
Losartan Potassium59$651
Furosemide108$590

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Mountain View

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →